La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

InnoCare Pharma Gestion

Gestion contrôle des critères 3/4

InnoCare Pharma's CEO is Jasmine Cui, appointed in Aug 2016, has a tenure of 8.75 years. total yearly compensation is CN¥22.63M, comprised of 20.8% salary and 79.2% bonuses, including company stock and options. directly owns 5.73% of the company’s shares, worth HK$538.08M. The average tenure of the management team and the board of directors is 2.9 years and 4.4 years respectively.

Informations clés

Jasmine Cui

Directeur général

CN¥22.6m

Rémunération totale

Pourcentage du salaire du PDG	20.8%
Durée du mandat du directeur général	8yrs
Propriété du PDG	5.7%
Durée moyenne d'occupation des postes de direction	2.9yrs
Durée moyenne du mandat des membres du conseil d'administration	4.4yrs

Mises à jour récentes de la gestion

Recent updates

Is There An Opportunity With InnoCare Pharma Limited's (HKG:9969) 36% Undervaluation?

Apr 11

Is InnoCare Pharma (HKG:9969) A Risky Investment?

Jan 25

Despite Lacking Profits InnoCare Pharma (HKG:9969) Seems To Be On Top Of Its Debt

Sep 05

InnoCare Pharma (HKG:9969) Is Using Debt Safely

Apr 30

InnoCare Pharma Limited's (HKG:9969) Intrinsic Value Is Potentially 100% Above Its Share Price

Nov 13

Despite Lacking Profits InnoCare Pharma (HKG:9969) Seems To Be On Top Of Its Debt

Oct 18

Analyse de la rémunération des PDG

Comment la rémunération de Jasmine Cui a-t-elle évolué par rapport aux bénéfices de InnoCare Pharma?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Mar 31 2024	n/a	n/a	-CN¥761m
Dec 31 2023	CN¥23m	CN¥5m	-CN¥631m
Sep 30 2023	n/a	n/a	-CN¥584m
Jun 30 2023	n/a	n/a	-CN¥867m
Mar 31 2023	n/a	n/a	-CN¥781m
Dec 31 2022	CN¥24m	CN¥4m	-CN¥887m
Sep 30 2022	n/a	n/a	-CN¥987m
Jun 30 2022	n/a	n/a	-CN¥296m
Mar 31 2022	n/a	n/a	-CN¥78m
Dec 31 2021	CN¥29m	CN¥3m	-CN¥65m
Sep 30 2021	n/a	n/a	CN¥60m
Jun 30 2021	n/a	n/a	-CN¥266m
Mar 31 2021	n/a	n/a	-CN¥329m
Dec 31 2020	CN¥120m	CN¥1m	-CN¥391m
Sep 30 2020	n/a	n/a	-CN¥2b
Jun 30 2020	n/a	n/a	-CN¥2b
Mar 31 2020	n/a	n/a	-CN¥2b
Dec 31 2019	CN¥17m	CN¥3m	-CN¥2b
Sep 30 2019	n/a	n/a	-CN¥742m
Jun 30 2019	n/a	n/a	-CN¥592m
Mar 31 2019	n/a	n/a	-CN¥571m
Dec 31 2018	CN¥26m	CN¥2m	-CN¥550m

Rémunération vs marché: La rémunération totale de Jasmine ($USD 3.16M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché Hong Kong ($USD 605.60K ).

Rémunération et revenus: Jasmine's compensation has been consistent with company performance over the past year.

PDG

Jasmine Cui (61 yo)

8yrs

Titularisation

CN¥22,626,000

Compensation

Dr. Jisong Cui, Ph.D. also known as Jasmine, has been Co-Founder InnoCare Pharma, Ltd. and serves as Chief Executive Officer of InnoCare Pharma, Ltd. since August 18, 2016 and its Chairwoman since Septembe...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Jisong Cui	Co-Founder	8yrs	CN¥22.63m	5.73% CN¥ 538.1m
Renbin Zhao	VP of Clinical Development & Medical Research and Executive Director	no data	CN¥4.06m	8.03% CN¥ 754.8m
Xin Fu	Chief Financial Officer	less than a year	pas de données	pas de données
Nan Gao	Chief Operating Officer	3.1yrs	pas de données	pas de données
Yue Tan	Accounting Supervisor	no data	pas de données	pas de données
Xiangyang Chen	Chief Technology Officer	4.8yrs	pas de données	0.0071% CN¥ 666.1k
Junsu Wang	General Counsel	2.9yrs	pas de données	pas de données
Xiang-Yang Zhang	Chief Medical Officer	no data	pas de données	pas de données
Davy Ouyang	VP & Head of Biology	2.9yrs	pas de données	pas de données
Jeff Chen	Chief Commercial Officer	less than a year	pas de données	pas de données
Bei Yuan	Secretary of the Board	no data	pas de données	pas de données
James Deng	Member of Scientific Advisory Board in Sales & Marketing	no data	pas de données	pas de données

2.9yrs

Durée moyenne de l'emploi

55yo

Âge moyen

Gestion expérimentée: 9969's management team is considered experienced (2.9 years average tenure).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Jisong Cui	Co-Founder	8.8yrs	CN¥22.63m	5.73% CN¥ 538.1m
Renbin Zhao	VP of Clinical Development & Medical Research and Executive Director	8.8yrs	CN¥4.06m	8.03% CN¥ 754.8m
James Deng	Member of Scientific Advisory Board in Sales & Marketing	no data	pas de données	pas de données
Arnold Levine	Member of Scientific Advisory Board	no data	pas de données	pas de données
Yigong Shi	Non-Executive Director & President of Scientific Advisory Board	8.8yrs	pas de données	0.18% CN¥ 16.5m
Zemin Zhang	Member of Scientific Advisory Board	8.8yrs	pas de données	pas de données
Zhanguo Li	Member of Scientific Advisory Board	no data	pas de données	pas de données
Ronggang Xie	Non-Executive Director	3.4yrs	pas de données	pas de données
Kai-Xian Chen	Independent Non-Executive Director	4.4yrs	pas de données	pas de données
Lan Hu	Independent Non-Executive Director	4.4yrs	pas de données	pas de données
Ming Jin	Non-Executive Director	2.4yrs	pas de données	pas de données
Dandan Dong	Independent Non-Executive Director	less than a year	pas de données	pas de données

4.4yrs

Durée moyenne de l'emploi

55.5yo

Âge moyen

Conseil d'administration expérimenté: 9969's board of directors are considered experienced (4.4 years average tenure).

InnoCare Pharma Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

InnoCare Pharma Appoints Xin Fu as Chief Financial Officer

Innocare Pharma Limited Announces the Appointment of Dandan Dong as Independent Non-Executive Director

Innocare Pharma Limited Announces Board Changes

Less than half of directors are independent

Less than half of directors are independent

Innocare Pharma Limited Announces Executive Changes

Recent updates

InnoCare Pharma Announces First Subject Dosed in Clinical Trial of TYK2 Inhibitor ICP-332 in the U.S

InnoCare Pharma Limited to Report First Half, 2024 Results on Aug 21, 2024

Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt?

InnoCare Pharma Announces the Acceptance of Biologics License Application for Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Adult Patients in China

InnoCare Pharma Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

First quarter 2024 earnings released: CN¥0.08 loss per share (vs CN¥0.007 loss in 1Q 2023)

Consensus revenue estimates decrease by 16%

Some Analysts Just Cut Their InnoCare Pharma Limited (HKG:9969) Estimates

InnoCare Pharma Limited to Report Q1, 2024 Results on May 14, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

InnoCare Pharma Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib

InnoCare Pharma Limited Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in China

Is InnoCare Pharma (HKG:9969) Weighed On By Its Debt Load?

InnoCare Pharma Limited Provides Earnings Guidance for the Year Ended 31 December 2023

InnoCare Announces First Pediatric Patient Dosed in Clinical Trial of pan-TRK Inhibitor Zurletrectinib in China

InnoCare Pharma Announces Clearance of Clinical Trial of BCL2 Inhibitor ICP-248 by U.S. FDA

New minor risk - Profitability

InnoCare Pharma Appoints Xin Fu as Chief Financial Officer

InnoCare Pharma Announces Latest Data of Oncology Pipelines Presented at the 65th Annual Meeting of ASH

Third quarter 2023 earnings released: CN¥0.062 loss per share (vs CN¥0.28 loss in 3Q 2022)

New minor risk - Profitability

InnoCare Pharma Announces First Patient Dosed in the Phase III Registrational Trial of Orelabrutinib for the Treatment of ITP in China

Innocare Pharma Limited Announces the Appointment of Dandan Dong as Independent Non-Executive Director

Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt?

InnoCare Pharma Limited (SEHK:9969) commences an Equity Buyback Plan for 149,967,323 shares, representing 8.5% of its issued share capital, under the authorization approved on June 2, 2023.

InnoCare Pharma Limited (SEHK:9969) commences an Equity Buyback Plan for 149,967,323 shares, representing 8.5% of its issued share capital, under the authorization approved on June 2, 2023.

InnoCare Pharma Announces Approval of Clinical Trial of SHP2 Inhibitor ICP-189 in Combination with EGFR Inhibitor Furmonertinib

InnoCare Announces Study Result of Orelabrutinib in Patients with r/r MZL Published by American Journal of Hematology

Second quarter 2023 earnings released: CN¥0.19 loss per share (vs CN¥0.24 loss in 2Q 2022)

Innocare Pharma Limited Announces Board Changes

InnoCare Pharma Limited to Report First Half, 2023 Results on Aug 30, 2023

Consensus EPS estimates upgraded to CN¥0.38 loss

Is InnoCare Pharma (HKG:9969) Using Too Much Debt?

First quarter 2023 earnings released: CN¥0.01 loss per share (vs CN¥0.08 loss in 1Q 2022)

No longer forecast to breakeven

Is There An Opportunity With InnoCare Pharma Limited's (HKG:9969) 36% Undervaluation?

No longer forecast to breakeven

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

InnoCare Pharma Limited Provides Earnings Guidance for the Year Ended 31 December 2022

InnoCare Pharma Limited Announces the Latest Clinical Result of FGFR Inhibitor Gunagratinib (ICP-192) for the Treatment of Cholangiocarcinoma Was Presented At 2023 American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium

Is InnoCare Pharma (HKG:9969) A Risky Investment?

InnoCare Pharma Limited Announces Approval of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Hong Kong

Now 27% undervalued

No longer forecast to breakeven

InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Orelabrutinib in Combination with Tafasitamab + Lenalidomide in China

InnoCare Pharma Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Mantle Cell Lymphoma in Singapore

Consensus revenue estimates increase by 12%

Third quarter 2022 earnings released: CN¥0.28 loss per share (vs CN¥0.17 profit in 3Q 2021)

Less than half of directors are independent

InnoCare Pharma Limited to Report Nine Months, 2022 Results on Nov 11, 2022

InnoCare Announces First Adolescent Patient Dosed in Clinical Trial of pan-TRK Inhibitor ICP-723 in China

Forecast to breakeven in 2024

InnoCare Pharma Limited has completed a Follow-on Equity Offering in the amount of CNY 2.672498 billion.

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in China

InnoCare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China

InnoCare Pharma Limited Announces Priority Review of Orelabrutinib for the Treatment of R/R MZL by NMPA

InnoCare Pharma Limited Announces Priority Review of Orelabrutinib for the Treatment of R/R MZL by NMPA

Despite Lacking Profits InnoCare Pharma (HKG:9969) Seems To Be On Top Of Its Debt

No longer forecast to breakeven

No longer forecast to breakeven

InnoCare Pharma Announces the Acceptance of the Biologics License Application for Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Hong Kong

Consensus revenue estimates fall by 10%

InnoCare Pharma and Keymed Biosciences Jointly Announce Approval of Clinical Trial of CCR8 Monoclonal Antibody CM369

First half 2022 earnings released: CN¥0.31 loss per share (vs CN¥0.16 loss in 1H 2021)

InnoCare Pharma Limited Provides Earnings Guidance for the Nine Months Ended 30 September 2022

InnoCare Pharma Announces Acceptance of Supplemental New Drug Application for Orelabrutinib in Relapsed or Refractory Marginal Zone Lymphoma in China

Innocare Pharma Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

InnoCare Pharma Limited Announces First Subject Dosed in Clinical Trial of TYK2 JH2 Allosteric Inhibitor ICP-488 in China